Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KILL QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

By: Business Wire

 

QurAlis Corporation requests that their press release NewsItemId: 20260224184980 “QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS” be killed. 

The release will be re-issued on Feb. 24, 2026.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.56
-5.55 (-2.64%)
AAPL  266.80
+2.22 (0.84%)
AMD  194.77
-5.38 (-2.69%)
BAC  51.22
-1.84 (-3.48%)
GOOG  310.76
-4.14 (-1.31%)
META  636.76
-18.89 (-2.88%)
MSFT  383.84
-13.39 (-3.37%)
NVDA  190.36
+0.54 (0.28%)
ORCL  139.88
-8.20 (-5.54%)
TSLA  394.81
-17.01 (-4.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.